% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Pellerin:267343,
author = {Pellerin, David and Danzi, Matt C and Renaud, Mathilde and
Houlden, Henry and Synofzik, Matthis and Zuchner, Stephan
and Brais, Bernard},
title = {{S}pinocerebellar ataxia 27{B}: {A} novel, frequent and
potentially treatable ataxia.},
journal = {Clinical and translational medicine},
volume = {14},
number = {1},
issn = {2001-1326},
address = {Hoboken, NJ},
publisher = {Wiley},
reportid = {DZNE-2024-00107},
pages = {e1504},
year = {2024},
abstract = {Hereditary ataxias, especially when presenting sporadically
in adulthood, present a particular diagnostic challenge
owing to their great clinical and genetic heterogeneity.
Currently, up to $75\%$ of such patients remain without a
genetic diagnosis. In an era of emerging disease-modifying
gene-stratified therapies, the identification of causative
alleles has become increasingly important. Over the past few
years, the implementation of advanced bioinformatics tools
and long-read sequencing has allowed the identification of a
number of novel repeat expansion disorders, such as the
recently described spinocerebellar ataxia 27B (SCA27B)
caused by a (GAA)•(TTC) repeat expansion in intron 1 of
the fibroblast growth factor 14 (FGF14) gene. SCA27B is
rapidly gaining recognition as one of the most common forms
of adult-onset hereditary ataxia, with several studies
showing that it accounts for a substantial number $(9-61\%)$
of previously undiagnosed cases from different cohorts.
First natural history studies and multiple reports have
already outlined the progression and core phenotype of this
novel disease, which consists of a late-onset slowly
progressive pan-cerebellar syndrome that is frequently
associated with cerebellar oculomotor signs, such as
downbeat nystagmus, and episodic symptoms. Furthermore,
preliminary studies in patients with SCA27B have shown
promising symptomatic benefits of 4-aminopyridine, an
already marketed drug. This review describes the current
knowledge of the genetic and molecular basis, epidemiology,
clinical features and prospective treatment strategies in
SCA27B.},
subtyp = {Review Article},
keywords = {Adult / Humans / Spinocerebellar Ataxias: diagnosis /
Spinocerebellar Ataxias: drug therapy / Spinocerebellar
Ataxias: genetics / Ataxia: complications / Phenotype /
4-aminopyridine (Other) / FGF14 (Other) / GAA-FGF14 ataxia
(Other) / cerebellar ataxia (Other) / genetics (Other) /
repeat expansion disorder (Other) / therapy (Other)},
cin = {AG Gasser},
ddc = {610},
cid = {I:(DE-2719)1210000},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38279833},
pmc = {pmc:PMC10819088},
doi = {10.1002/ctm2.1504},
url = {https://pub.dzne.de/record/267343},
}